07-05-2019 | Multiple sclerosis | Video
AAN 2019: CHORDS sheds light on safety and effectiveness of ocrelizumab in real-world setting
Thomas Leist takes us through the 1-year interim analysis of the CHORDS study of ocrelizumab comprising multiple sclerosis patients drawn from community practice (2:04).
Funding for independent interviews at AAN 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.